EUVIMED · CrossrefJournal
Global and Regional Health Technology Assessment
ISSN 2283-5733 · Aboutscience Srl
Latest articles
Oncology drug expenditure governance in an antineoplastic drug unit: comparative economic analysis 2023–2025 and the stratified recovery rate
AIFA monitoring registries as a strategic tool in the Italian HTA framework: evolution and policy implications
Implementing the EU HTA Regulation in Italy: a multi-stakeholder perspective from the Mogliano Veneto Working Group
The role of osimertinib in the therapeutic pathway of EGFR-mutated NSCLC: results from an Italian Delphi Consensus
Integrating MCDA and economic evaluation into a rule-based framework for hospital-level health technology assessment
Burden of primary biliary cholangitis on the Italian National Health Service: retrospective analysis from an administrative database
Pharmacoeconomic analysis of switch to faricimab for neovascular age-related macular degeneration in real clinical practice
Comments on: Use of artificial intelligence to draft a mini-HTA report on a new medical device belonging to class IIb-III
A decision algorithm for interpreting immature overall survival in onco‑hematology: development and application
Impact of AIFA Note 100 on innovative antidiabetic prescribing eligibility in two Italian local health authorities: drug utilization and patient characteristics
Impact of Ministerial Decree 77/2022 from different stakeholders’ perspectives: clinicians, pharmacists, patients, and industry
Comments on: Italian Medicines Agency’s reform and time until pricing and reimbursement decisions: a time-to-event analysis
Author’s reply to comments to: Italian Medicines Agency’s reform and time until pricing and reimbursement decisions: a time-to-event analysis
Optimizing CAR-T therapy delivery in the Italian healthcare system: economic and organizational insights in follicular lymphoma
Procedural activity and dynamics of the new Italian Scientific and Economic Committee (CSE): a one-year observational analysis
The AIFA reform and evaluation timelines for new drugs: the impact of the Scientific and Economic Commission
More and earlier data from AIFA: do they impact on the regional policies? Results from an exploratory analysis
Cost minimization analysis of subcutaneous and intravenous immunoglobulin treatment in Italy
A guide to critical reading of influenza vaccine cost-effectiveness analyses
Re-discussions in the decision process of the Italian Medicine Agency: a quantitative assessment of causes and implications
Italian Medicines Agency’s reform and time until pricing and reimbursement decisions: a time-to-event analysis
How Regions can leverage the OsMed Report to disseminate initiatives aimed at improving appropriateness
The societal costs associated with patients with chronic spontaneous urticaria (CSU) in Italy
Use of artificial intelligence to draft a mini-HTA report on a new medical device belonging to class IIb–III
What is needed to successfully implement the EU HTA Regulation enabling broad patient access in Europe
How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality
Economic burden of disease of uncontrolled acromegalic patients: the acromegaly Italian collaborative study group
Burden of disease, healthcare pathways and costs of cardiovascular high-risk patients with type 2 diabetes: a real world analysis
Assessing social and economic impact of subcutaneous mAbs in oncology
A comparative examination of healthcare use related to hearing impairment in Europe
EUVIMED